U.S. Liposomal Doxorubicin Market, by Drug Type (Branded and Generic), by Cancer Type (Ovarian Cancer, AIDS-related Kaposi’s Sarcoma, Multiple Myeloma, and Others), and by States (California, Texas, Florida, New York, Pennsylvania, Illinois, Ohio, Georgia

U.S. Liposomal Doxorubicin Market, by Drug Type (Branded and Generic), by Cancer Type (Ovarian Cancer, AIDS-related Kaposi’s Sarcoma, Multiple Myeloma, and Others), and by States (California, Texas, Florida, New York, Pennsylvania, Illinois, Ohio, Georgia, North Carolina, Michigan, New Jersey, Virginia, Washington, Arizona, and Others) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Liposomal doxorubicin is a chemotherapy drug, which is administered intravenously to treat AIDS-related Kaposi's sarcoma, breast cancer, ovarian cancer, and other solid tumors. Doxorubicin acts by blocking an enzyme called topoisomerase 2 that cancer cells need in order to divide and grow. Liposomal delivery of doxorubicin HCL (Hydrochloride) improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects. Some side effects of using Doxil or doxorubicin hydrochloride liposome include low blood counts, hand-to-foot syndrome (palmar-plantar erythrodysesthesia), mouth sores, infusion-related side effects: shortness of breath, facial swelling, headache, back pain, flushing, tightness in the chest and throat, and/or low blood pressure.
Market Dynamics
The increasing prevalence of cancer is expected to drive demand for liposomal doxorubicin for treatment of the disease and aid in growth of the U.S. liposomal doxorubicin market. For instance, according to the American Cancer Society, in 2017, cancer was the second most common cause of death in the U.S., and accounted for nearly one out of four deaths. Moreover, according to National Cancer Institute, in 2021, around 1.8 million people were diagnosed with cancer in the U.S., and around 276,480 women and 2,670 men were diagnosed with breast cancer.
Key features of the study:
This report provides in-depth analysis of the U.S. liposomal doxorubicin market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the U.S. liposomal doxorubicin market based on the following parameters – company highlights, types portfolio, key highlights, financial performance, and market strategies
Key companies covered as a part of this study include Johnson & Johnson, Baxter International Inc., Sun Pharmaceutical Industries Ltd., and Dr. Reddy’s Laboratories, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The U.S. liposomal doxorubicin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. liposomal doxorubicin market
Detailed Segmentation:
U.S. Liposomal Doxorubicin Market, By Drug Type:
Branded
Generic
U.S. Liposomal Doxorubicin Market, By Cancer Type:
Ovarian Cancer
AIDS-related Kaposi’s Sarcoma
Multiple Myeloma
Others
U.S. Liposomal Doxorubicin Market, By States:
California
Texas
Florida
New York
Pennsylvania
Illinois
Ohio
Georgia
North Carolina
Michigan
New Jersey
Virginia
Washington
Arizona
Others
Company Profiles
Johnson & Johnson*
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Market Strategies
Baxter International Inc.
Sun Pharmaceutical Industries Ltd.
Dr. Reddy’s Laboratories, Inc.
“*” marked represents similar segmentation in other categories in the respective section.